About
MaxWell Biomedical develops device-based cardiac resynchronization therapy (CRT-A) designed to restore both sinus rhythm and atrial mechanical function in patients with atrial fibrillation and related heart failure conditions without damaging atrial tissue.
Explore MaxWell Biomedical's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.